Profil bibliographique

Christie Woods

Informations fournies par OpenAlex. Research Africa ne déduit ni nationalité, ni poste, ni coordonnées personnelles.

11Publications signalées

302Citations signalées

1Affiliations récentes

Institutions déclarées

Royal Liverpool and Broadgreen University Hospital NHS Trust

Domaines associés

SARS-CoV-2 and COVID-19 ResearchCOVID-19 Clinical Research StudiesSARS-CoV-2 detection and testingMosquito-borne diseases and controlRespiratory viral infections research

Publications récentes

Accès ouvert 2022 articleOpenAlex

Characterisation of SARS-CoV-2 genomic variation in response to molnupiravir treatment in the AGILE Phase IIa clinical trial

I’ah Donovan-Banfield, Rebekah Penrice-Randal, Hannah Goldswain, Aleksandra Rzeszutek et autres

42 citationsNature Communications

Accès ouvert 2022 articleOpenAlex

Molnupiravir versus placebo in unvaccinated and vaccinated patients with early SARS-CoV-2 infection in the UK (AGILE CST-2): a randomised, placebo-controlled, double-blind, phase 2 trial

Saye Khoo, Richard J. Fitzgerald, Geoffrey Saunders, Calley Middleton et autres

81 citationsThe Lancet Infectious Diseases

Accès ouvert 2022 preprintOpenAlex

A Randomised -Controlled Phase 2 trial of Molnupiravir in Unvaccinated and Vaccinated Individuals with Early SARS-CoV-2

Saye Khoo, Richard J. Fitzgerald, Geoffrey Saunders, Calley Middleton et autres

3 citationsmedRxiv

Accès ouvert 2022 preprintOpenAlex

Characterisation of SARS-CoV-2 genomic variations in response to molnupiravir treatment in the AGILE Phase IIa clinical trial.

I’ah Donovan-Banfield, Rebekah Penrice-Randal, Hannah Goldswain, Aleksandra Rzeszutek et autres

2 citationsResearch Square

2022 datasetOpenAlex

ZIKAVAC: a first in person trial of a novel vaccine to prevent Zika virus disease

Hayley Hardwick, Richard J. Fitzgerald, Neil French, Christie Woods

0 citationshttp://isrctn.com/

Accès ouvert 2021 articleOpenAlex

An Open Label, Adaptive, Phase 1 Trial of High‐Dose Oral Nitazoxanide in Healthy Volunteers: An Antiviral Candidate for SARS‐CoV‐2

Lauren Walker, Richard J. Fitzgerald, Geoffrey Saunders, Rebecca Lyon et autres

30 citationsClinical Pharmacology & Therapeutics

Accès ouvert 2021 preprintOpenAlex

An open label, adaptive, phase 1 trial of high-dose oral nitazoxanide in healthy volunteers: an antiviral candidate for SARS-CoV-2

Lauren Walker, Richard J. Fitzgerald, Geoffrey Saunders, Rebecca Lyon et autres

0 citationsmedRxiv

Accès ouvert 2021 articleOpenAlex

Optimal dose and safety of molnupiravir in patients with early SARS-CoV-2: a Phase I, open-label, dose-escalating, randomized controlled study

Saye Khoo, Richard J. Fitzgerald, Sean Ewings, Thomas Jaki et autres

118 citationsJournal of Antimicrobial Chemotherapy

Accès ouvert 2021 articleOpenAlex

AGILE: a seamless phase I/IIa platform for the rapid evaluation of candidates for COVID-19 treatment: an update to the structured summary of a study protocol for a randomised platform trial letter

Gareth Griffiths, Richard J. Fitzgerald, Thomas Jaki, Andrea Corkhill et autres

20 citationsTrials

Accès ouvert 2021 preprintOpenAlex

Optimal dose and safety of molnupiravir in patients with early SARS-CoV-2: a phase 1, dose-escalating, randomised controlled study

Saye Khoo, Richard J. Fitzgerald, Sean Ewings, Thomas Jaki et autres

6 citationsmedRxiv

Accès ouvert 2021 preprintOpenAlex

AGILE: A Seamless Phase I/IIa Platform for the Rapid Evaluation of Candidates for COVID-19 treatment: An update to the structured summary of a study protocol for a randomised platform trial letter

Gareth Griffiths, Richard J. Fitzgerald, Thomas Jaki, Andrea Corkhill et autres

0 citationsResearch Square

Notice OpenAlex

BNTIC News n’est pas le producteur de ces données. Recherche à la demande dans Crossref et Europe PMC, sans clé ; OpenAlex reste optionnel. Aucun service payant requis, aucune réponse conservée. Sources et limites.